DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo

TESARO (NASDAQ: TSRO)

36.99 0.19 (0.52%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TSRO $36.99 0.52%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $37.12
Previous Close $36.80
Daily Range $36.68 - $37.25
52-Week Range $22.15 - $40.99
Market Cap $1.3B
P/E Ratio -8.82
Dividend (Yield) $0.00 (0.0%)
Volume 150,035
Average Daily Volume 412,349
Current FY EPS -$4.57

Sector

Healthcare

Industry

Drugs

TESARO (TSRO) Description

TESARO Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. Website: http://www.tesarobio.com/

News & Commentary

What Was Behind Tesaro Inc.'s 21% Pop?

Tesaro and Opko's rolapitant successfully achieved primary and secondary endpoints in reducing chemotherapy-induced nausea and vomiting.

TSRO: Insiders Vs. Shorts

Myriad Genetics, Tesaro Tie Up for myChoice Cancer Test - Analyst Blog

TESARO's (TSRO) CEO Lonnie Moulder on Q3 2014 Results - Earnings Call Transcript

Benzinga's Top Initiations

Weakness Seen in Tesaro, Inc. (TSRO): Stock Tumbles 9.0% - Tale of the Tape

TESARO Announces Offering of $165 Million of Convertible Senior Notes Due 2021

TRACON Pharmaceuticals Completes $27M Financing And Expands Management Team And Board of Directors

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog

Sector Update: Health Care Stocks End Mixed; Opko Health, Tesaro Climb After Submitting New Drug Ap

Sector Update: Health Care Stocks End Mixed; Opko Health, Tesaro Climb After Submitting New Drug Application for Anti-Nausea Medication

Sector Update: Health Care

See More TSRO News...